Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.

@article{mills1992ClopidogrelIT,
  title={Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase.},
  author={david. c. mills and Rajesh Puri and C J Hu and Caterina P Minniti and Generosa Grana and Michael D. Freedman and Roberta F. Colman and Robert W. Colman},
  journal={Arteriosclerosis and thrombosis : a journal of vascular biology},
  year={1992},
  volume={12 4},
  pages={430-6}
}
Clopidogrel, like the homologous thienopyridine derivative ticlopidine, selectively inhibits platelet aggregation induced by ADP. We have previously described two nucleotide-binding sites on platelets related to ADP-mediated platelet responses. The first is a high-affinity binding site for 2-methylthio-ADP (2-MeSADP) that is linked to the inhibition of stimulated adenylate cyclase. The second is the 100-kd exofacial membrane protein aggregin, which is labeled by the reactive ADP analogue 5'-p… CONTINUE READING